In a woman with migraine without aura currently taking Junel 1.5/30 who wants to lower estrogen to ≤20 µg and shorten or eliminate the hormone‑free interval, which of the listed combined oral contraceptives—Ashlyna, Jolessa (drospirenone/ethinyl estradiol), Zafemy, Blisovi, Estarylla, Syeda, Loryna, Apri (norethindrone acetate/ethinyl estradiol), Tri‑Sprintec—are appropriate?

Best Contraceptive Options for Migraine Without Aura with Lower Estrogen and Shortened Hormone-Free Interval

For a woman with migraine without aura currently on Junel 1.5/30 who wants ≤20 µg estrogen and a shortened or eliminated hormone-free interval, the best options from your list are Loryna (drospirenone 3 mg/ethinyl estradiol 20 µg in a 24/4 regimen) or Blisovi Fe 1/20 (norethindrone acetate 1 mg/ethinyl estradiol 20 µg), with Loryna being preferred due to its inherently shorter hormone-free interval. 12

Why These Two Options Stand Out

Loryna (Drospirenone 3 mg/Ethinyl Estradiol 20 µg, 24/4 Regimen)

• Loryna contains 20 µg ethinyl estradiol, meeting the patient's goal of lowering estrogen from her current 30 µg dose. 12

• The 24/4 regimen (24 active pills + 4 placebo pills) provides a significantly shorter hormone-free interval than traditional 21/7 formulations, which is crucial for preventing estrogen-withdrawal migraine. 331

• A prospective randomized study specifically demonstrated that the 24/4 regimen with drospirenone 3 mg/ethinyl estradiol 20 µg significantly reduced both the intensity and duration of menstrual migraine compared to a 21/7 regimen with the same hormones. 2

• The shorter hormone-free interval reduces follicular activity and improves contraceptive reliability, particularly important when using lower-dose estrogen formulations. 31

• Loryna can be used continuously (skipping the placebo pills entirely) to eliminate the hormone-free interval completely if breakthrough bleeding or migraine persists. 445

Blisovi Fe 1/20 (Norethindrone Acetate 1 mg/Ethinyl Estradiol 20 µg)

• Blisovi Fe 1/20 contains 20 µg ethinyl estradiol, meeting the lower estrogen requirement. 6

• While Blisovi comes in a traditional 21/7 formulation, it can be prescribed for continuous or extended-cycle use by instructing the patient to skip the iron placebo pills and start a new pack immediately. 335

• Norethindrone acetate is a second-generation progestin with a favorable safety profile and lower thrombotic risk compared to third-generation progestins or drospirenone. 7

Why Other Options Are Not Appropriate

Ashlyna, Jolessa, Zafemy (Extended-Cycle Formulations)

• These are extended-cycle formulations typically containing 30 µg ethinyl estradiol (or higher), which does not meet the patient's goal of ≤20 µg estrogen. 33

• While extended cycles are beneficial for migraine management, the higher estrogen dose makes these inappropriate for this specific patient request. 44

Estarylla, Syeda, Tri-Sprintec

• Estarylla and Syeda typically contain 30-35 µg ethinyl estradiol, exceeding the patient's desired ≤20 µg threshold. 33

• Tri-Sprintec is a triphasic formulation with varying hormone doses throughout the cycle, which is not recommended for migraine management as monophasic formulations provide more stable hormone levels. 1

• These formulations use traditional 21/7 regimens and would require modification to continuous use to shorten the hormone-free interval. 33

Apri (Desogestrel 0.15 mg/Ethinyl Estradiol 30 µg)

• Apri contains 30 µg ethinyl estradiol, not meeting the ≤20 µg requirement. 8

• Desogestrel is a third-generation progestin associated with higher venous thromboembolism risk compared to second-generation progestins. 7

Critical Safety Considerations for Migraine Without Aura

• Combined hormonal contraceptives are safe in women with migraine WITHOUT aura, but are absolutely contraindicated in women with migraine WITH aura due to increased stroke risk. 449

• If the patient develops migraine with aura while using combined hormonal contraceptives, the medication must be discontinued immediately and alternative contraception (progestin-only methods or non-hormonal options) should be initiated. 449

• Lower-dose estrogen formulations (≤20 µg) show greater follicular activity when pills are missed, making strict adherence counseling essential. 31

Implementation Strategy

Initial Prescription Approach

• Start with Loryna using the standard 24/4 regimen for the first 2-3 cycles to assess tolerance and migraine response. 12

• If menstrual migraine persists during the 4-day hormone-free interval, transition to continuous use by instructing the patient to skip the white placebo pills and start a new pack immediately. 345

• Provide backup contraception counseling: if starting >5 days after menstrual bleeding, use condoms or abstain for 7 consecutive days. 31

Missed Pill Management (Critical for 20 µg Formulations)

• If ≥2 consecutive active pills are missed (≥48 hours), use backup contraception for 7 days after resuming pills. 31

• If pills are missed during the last active-pill week (days 15-24 for Loryna), omit the hormone-free interval by starting a new pack immediately. 31

• If pills are missed during the first active-pill week and unprotected intercourse occurred in the prior 5 days, consider emergency contraception. 31

Alternative if Loryna Is Not Tolerated

• Switch to Blisovi Fe 1/20 prescribed for continuous use (skip iron pills, start new pack immediately). 65

• Norethindrone acetate may have fewer side effects related to mineralocorticoid activity (bloating, breast tenderness) compared to drospirenone. 7

Monitoring and Follow-Up

• Evaluate migraine frequency, severity, and disability at 2-3 months using a headache diary. 44

• If breakthrough bleeding becomes problematic with continuous use, allow a planned 3-4 day hormone-free interval every 3-4 months. 35

• If migraine control remains inadequate despite optimized hormonal contraception, consider adding perimenstrual prophylaxis with frovatriptan or naratriptan for 5 days starting 2 days before the anticipated hormone-free interval (if using cyclic regimen). 410

• Women who frequently miss pills should be counseled about long-acting reversible contraception (IUD, implant, or injectable) as more reliable alternatives. 331

Common Pitfalls to Avoid

• Do not prescribe formulations with >20 µg estrogen when the patient specifically requests lower doses—this undermines shared decision-making and may worsen migraine. 32

• Do not use multiphasic formulations (like Tri-Sprintec) for migraine management—stable hormone levels are preferable. 1

• Do not forget to counsel about the increased importance of adherence with 20 µg formulations—missing pills carries higher pregnancy risk than with 30-35 µg formulations. 31

• Do not continue combined hormonal contraceptives if the patient develops migraine with aura—this is an absolute contraindication. 449